Disease Pharma Companies Small Molecule 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Several of the large pharma companies have recently re-entered the dementia field.
Drug Discovery World
MAY 1, 2024
This is reflected in collaboration and investment patterns; in 2023, Antiverse, a biotechnology company developing a computational antibody drug discovery platform, raised seed funding totalling £1.4 Research will likely focus on expanding applications in infectious diseases and autoimmune disorders.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 22, 2020
Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). and IL-18, which are believed to be a driving force behind several chronic inflammatory conditions.
Drug Discovery World
APRIL 27, 2023
Dr Mansley also comments that the multitude of biotech and pharma companies in the Greater Boston region means that people regularly move organisations. She said: “When one of our customers leaves a company and moves to a new one up the street, they often get in touch with us, which helps us grow new business.
The Pharma Data
SEPTEMBER 29, 2020
The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas.
The Pharma Data
JANUARY 24, 2021
.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., Preclinical and clinical programs at Northern Biologics were acquired by big pharma companies in 2020.
Drug Discovery World
APRIL 3, 2023
Also, the large, immunogenic nature of antibodies and protein ligands as therapeutic molecules means our partners are looking for alternative solutions that offer reduced immunogenicity and improved tissue penetration properties. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies.
Expert insights. Personalized for you.
130 
Let's personalize your content